Chiesi: key pharmaceutical brand products| ��ƽ��

Key brand name drugs produced by the Italian pharmaceutical company Chiesi from 2016 to 2019, by revenue (in million euros)

Characteristic	2016	2017	2018	2019
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Release date

2020

More information

Region

Italy

Survey time period

2016 to 2019

Supplementary notes

The source adds the following information: “The brand drugs mentioned refers to the respiratory therapeutic class, the one in which Chiesi is a key player at global level”.

Citation formats

Foster, Curosurf and Clenil are the key brand name drugs to treat problems of the respiratory area, developed and marketed by the Italian pharmaceutical company Chiesi. In 2019, Foster generated the largest sales revenue, with *** million euros. Curosurf and Clenil followed far behind with revenue amounting to *** and *** million euros, respectively.

Chiesi in the domestic and international market

 Chiesi is among the leading Italian pharmaceutical companies based on revenue, as well as one of the European firms of this sector with the greatest level of investments in research and development. The company established itself on the pharmaceutical market back in 1979, specifically thanks to the launch of Clenil, which is, as above mentioned, still one of its key products.  

Research and development

Nowadays, Chiesi’s focus is within the respiratory area, primary care, neonatology and rare diseases. In addition, the company has recently started to explore the field of regenerative medicine and to develop eco-friendly and innovative products. Their increasing investments in research and development may suggest that innovation plays a key role in Chiesi’s business model.